WO2006016930A3 - Methods for treating hcv infection - Google Patents
Methods for treating hcv infection Download PDFInfo
- Publication number
- WO2006016930A3 WO2006016930A3 PCT/US2005/016927 US2005016927W WO2006016930A3 WO 2006016930 A3 WO2006016930 A3 WO 2006016930A3 US 2005016927 W US2005016927 W US 2005016927W WO 2006016930 A3 WO2006016930 A3 WO 2006016930A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- reducing
- hcv
- hcv infection
- infection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57132204P | 2004-05-14 | 2004-05-14 | |
US60/571,322 | 2004-05-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006016930A2 WO2006016930A2 (en) | 2006-02-16 |
WO2006016930A3 true WO2006016930A3 (en) | 2006-08-03 |
Family
ID=35839691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/016927 WO2006016930A2 (en) | 2004-05-14 | 2005-05-13 | Methods for treating hcv infection |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006016930A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299038B2 (en) | 2000-05-23 | 2012-10-30 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1736478B1 (en) | 2000-05-26 | 2015-07-22 | IDENIX Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
RU2005118421A (en) | 2002-11-15 | 2006-01-20 | Айденикс (Кайман) Лимитед (Ky) | 2'-BRANCHED NUCLEOSIDES AND MUTATION FLAVIVIRIDAE |
BRPI0516825A (en) * | 2004-10-01 | 2008-09-23 | Vertex Pharma | hepatitis c virus protease ns3-ns4a inhibition (vhc) |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2061513B1 (en) * | 2007-09-14 | 2011-08-10 | Schering Corporation | Method of treating hepatitis c patients |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8809265B2 (en) | 2011-10-21 | 2014-08-19 | Abbvie Inc. | Methods for treating HCV |
DK2583677T1 (en) | 2011-10-21 | 2015-01-19 | Abbvie Inc | Methods for treatment of HCV comprising at least two direct-acting antiviral agents ribavirin, interferon but not |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
KR20150074051A (en) | 2012-10-19 | 2015-07-01 | 브리스톨-마이어스 스큅 컴퍼니 | Hepatitis c virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
JP7129703B2 (en) | 2016-04-28 | 2022-09-02 | エモリー ユニバーシティー | Alkyne-Containing Nucleotide and Nucleoside Therapeutic Compositions and Uses Associated Therewith |
-
2005
- 2005-05-13 WO PCT/US2005/016927 patent/WO2006016930A2/en active Application Filing
Non-Patent Citations (5)
Title |
---|
FRESE M. ET AL.: "Interferon-gamma Inhibits Replication of Subgenomic and Genomic Hepatitis C virus RNAs", HEPATOLOGY, vol. 35, no. 3, March 2002 (2002-03-01), pages 694 - 703, XP002999943 * |
HULTGREN C. ET AL.: "The antiviral compound ribavirin modulates the T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses", J. GENE VIROL., vol. 79, no. 10, October 1998 (1998-10-01), pages 2381 - 2391, XP002999944 * |
RICE C.M. ET AL.: "Hepatitis C virus-specific T lymphocyte responses", CURRENT OPINION IN IMMUNOLOGY, vol. 7, no. 4, August 1995 (1995-08-01), pages 532 - 538, XP002999945 * |
SNELL N.: "Ribavirin-current status of a broad spectrum antiviral agent", EXPERT OPIN. PHARMACOTHER., vol. 2, no. 8, August 2001 (2001-08-01), pages 1317 - 1324 * |
WANG Q.M. ET AL.: "Recent advances in prevention and treatment of hepatitis C virus infectious", PROG. DRUG RES., September 2001 (2001-09-01), pages 79 - 110 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8299038B2 (en) | 2000-05-23 | 2012-10-30 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
Also Published As
Publication number | Publication date |
---|---|
WO2006016930A2 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006016930A3 (en) | Methods for treating hcv infection | |
WO2005013917A3 (en) | Combination therapy for treating alphavirus infection and liver fibrosis | |
Loustaud-Ratti et al. | Ribavirin: Past, present and future | |
WO2005067454A3 (en) | Combination therapy for treating hepatitis c virus infection | |
Pawlotsky et al. | Antiviral action of ribavirin in chronic hepatitis C | |
Lee et al. | New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials | |
WO2010039801A3 (en) | Methods of treating hepatitis c virus infection | |
WO2006033995A3 (en) | Thiazolidin-4-ones having anti-hepatitis b activity | |
WO2009039248A8 (en) | Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection | |
JP2008518943A5 (en) | ||
WO2008082601A3 (en) | Compounds and pharmaceutical compositions for the treatment of viral infections | |
JP2002515453A5 (en) | ||
WO2009061395A3 (en) | Hcv combination therapies comprising vx-950, peg-ifn and ribavirin | |
WO2005110455A3 (en) | Combination therapy for treating hepatitis virus infection | |
WO2004110392A3 (en) | Compositions and methods for treating coronavirus infection and sars | |
WO2006045616A3 (en) | β-L-N4-HYDROXYCYTOSINE DEOXYNUCLEOSIDES AND THEIR USE AS PHARMACEUTICAL AGENTS IN THE PROPHYLAXIS OR THERAPY OF VIRAL DISEASES | |
Buster et al. | Peginterferon for the treatment of chronic hepatitis B in the era of nucleos (t) ide analogues | |
WO2005016288A3 (en) | Methods and compositions for treatment of viral diseases | |
WO2000018417A3 (en) | Treatment of hepatitis b infection with thymosin alpha 1 and lamivudine | |
MD2549F1 (en) | Method of treatment of the chronic viral hepatitis C | |
UA95299C2 (en) | Prophylactic or therapeutic agent for viral disease caused by hepatitis c virus | |
WO2004052905A3 (en) | Antiviral nucleoside derivatives | |
WO2010081095A3 (en) | Methods and compositions for inhibiting hepatitis c virus replication | |
WO2008073864A8 (en) | Novel combinations | |
Beckebaum et al. | Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |